Denosumab, a monoclonal antibody targeting RANKL, is being evaluated for its potential to reduce the risk of progression from smoldering multiple myeloma (SMM) to multiple myeloma (MM). The market for MM therapies is competitive, with established players like Bristol-Myers Squibb and Johnson & Johnson. If successful, this study could position Denosumab as a preventive treatment option in the SMM segment, potentially expanding its use beyond osteoporosis and bone-related complications in cancer. The collaboration with Amgen, a leader in monoclonal antibody therapies, may enhance development and commercialization efforts.